• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Gilead Has Become and Will Be a Volatile Name

I would consider any entry a trade, and not an investment.
By STEPHEN GUILFOYLE
Feb 24, 2020 | 11:04 AM EST
Stocks quotes in this article: GILD

Re-Focusing. 4 pm. Tuesday, February 4th. The closing bell had literally just finished with its business for the day. Gilead (GILD) reported the firm's fourth quarter numbers. The adjusted EPS print was a mess, missing consensus expectations by 37 cents. Revenue generation did show a small year over year increase, and actually managed to beat the street. The firm did increase the dividend. The stock sold off fairly hard in response. The reaction from the analyst community was less than enthusiastic. There were cuts made to both rating and target prices on the days that followed. None of that matters very much right now.

Matters Now

Gilead has been in almost a perpetual search for a performance driver ever since sales for the firm's Hepatitis C treatment plummeted in 2016. In fact, the firm has now posted adjusted EPS in decline for 15 of the last 16 quarters. The firm has worked on treatments for cancer, Ebola, arthritis, and HIV in recent years. It was that Ebola treatment (Remdesivir), still experimental, that Gilead sent to China for clinical testing as an anti-viral candidate for treating what we now know as Covid-19. As long as the planet is frightened. As long as the world continues to become a less certain place as far as the future of this virus is concerned, and until definable results are in for this potential treatment, Gilead has become, and will be a volatile name.

There is a problem though. As first reported nearly a week ago in the Wall Street Journal, and reiterated going into the weekend at the South China Morning Post, these clinical tests that are being run in 10 Wuhan area hospitals are finding it difficult in finding enough recruits that fit the intended requirements going in to the tests.

The original intention was to recruit a total of 761 patients, 452 with symptoms considered to be severe, and 308 with mild to moderate symptoms. To qualify, the severe patients had to still be within a 12 day window of the onset of infection, and could not have been treated by any other means over the prior 30 days. Mild to moderate patients had to be within eight days of onset. All 761 patients had to have tested positive for Covid-19. The article in the Morning Post stated that more than 200 severe patients and more than 30 mild to moderate patients had been recruited.

Results

Still drawing from the piece at the Morning Post, Gilead Chief Medical Officer Merdad Parsey informed Chinese state-run news agency Xinhua that the company did not expect to see results until April. However, Tedros Adhanom Ghebreyesus, director general at the WHO (World Health Organization) told the press last week that there could be preliminary results available for this treatment as well as others within three weeks.

On Friday, Chinese Vice Minister Xu Nanping told the media that in-vitro testing of Remdesvir have so far shown a "very good inhibiting effect" and that he awaits the clarity of the pending clinical results.

My Thoughts

Should traders enter right here? I'm not always right, but I am not.

The shares now trade at a 15 month high. These clinical tests pan out well and there will be a pop in this stock, forget that the shares look overbought. That means nothing right now. Would I reconsider later this week, if we should see a reversal in the market's overall risk-off behavior? Perhaps close to the 50 day SMA.

I would consider any entry a trade, and not an investment if I indeed did go that route. In the meantime, a $75/$80 April 17th bull call spread could be worth the risk of a roughly $2 net debit, but I would not risk more than $2 to win back $5. With tech trading the way it is this morning, there are bigger fish to fry, and I am fishing. For trades.

Remember, this is no time to feel married to any stock. No need to love anything that can't love you back.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle had no position in the securities mentioned.

TAGS: Drug Approvals | Investing | Markets | Stocks | Technical Analysis | Trading | Pharmaceuticals | China | Stock of the Day

More from Investing

Price Targets: How They Mislead and How They Can be Used

James "Rev Shark" DePorre
Jan 23, 2021 10:00 AM EST

The main problem with price targets is that they are a static number in a dynamic situation.

Stock Market Continues to Defy Conventional Wisdom

James "Rev Shark" DePorre
Jan 22, 2021 5:04 PM EST

Concerns about the action being overheated remain, but rotational action keeps the momentum going.

AMC Is a High Risk, High Reward Play

Timothy Collins
Jan 22, 2021 2:15 PM EST

Short and sweet: This is based on the high running emotions of the markets. There's little to it beyond that.

GoodRx Needs a Shot in the Arm to Improve Its Outlook

Bruce Kamich
Jan 22, 2021 2:03 PM EST

IPOs in recent months have done extremely well -- not so GDRX.

2021 and 2022 Look Difficult for Intel, While 2023 -- Might -- Be Better

Eric Jhonsa
Jan 22, 2021 1:44 PM EST

Competition from AMD and ARM CPU developers looks set to take a toll over the next two years. But Intel could be in better shape in 2023 if its new CEO is ready to make some tough choices.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    I discuss price targets in my Saturday column.
  • 07:54 AM EST GARY BERMAN

    Friday Morning Fibocall for 1/22/2021

    SPX (Long-Term View) The 1/21/21 NEW high @ 3861...
  • 11:16 AM EST CHRIS VERSACE

    Worst Stocks to Buy for the Biden Presidency

    Biden's take on the minimum wage, likely moves on ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login